PCRXPacira BioSciences Inc

DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION PR...

A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC PR Newswire MIAMI, May 21, 2026 FRANK LEE AND THE BOARD HAVE OVERSEEN GROSS AND PERSISTENT UNDERPERFORMANCE FOR YEARS. WHY...

DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences PR Newswire MIAMI, May 20, 2026 Independent Directors, Christopher Dennis, MD, MBA, FAPA and Oliver Benton "Ben" Curtis III Outline...

Royal Bank Of Canada raised their price target on shares of Pacira BioSciences from $22.00 to $24.00 and gave the company a "sector perform" rating in a research report on Friday...

PCRX Q1 earnings miss estimates as rising costs weigh on profit, but revenues top expectations on Exparel demand and growth from Zilretta and iovera.

Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up After Analyst Upgrade...

Key PointsCFO Shawn Cross exercised and sold 12,941 shares on April 23, 2026, for a transaction value of ~$326,000 at around $25.16 per share...

Needham & Company LLC boosted their target price on Pacira BioSciences from $30.00 to $32.00 and gave the stock a "buy" rating in a report on Friday...

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) issued its quarterly earnings results on Thursday. The company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.61 by...